Bioxyne Limited

BXN

AU000000BXN6

Biotechnology & Medical Research

Market Closed - Australian S.E. Other stock markets 01:59:42 2024-06-14 EDT			5-day change	1st Jan Change
0.006 ^AUD	0.00%		+20.00%	-45.45%

05-14	Bioxyne to Release Shares from Escrow; Shares Up 17%	MT
05-14	Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia	MT

Bioxyne Limited Announces Resignation of Peter French from the Board

February 15, 2018 at 02:19 am

Bioxyne Limited advised that Peter French has resigned from the Board with effect from February 15, 2018.

Latest news about Bioxyne Limited

Bioxyne to Release Shares from Escrow; Shares Up 17%	05-14	MT
Bioxyne Subsidiary, CY Biopharma Enter Partnership to Advance Novel Psilocybin Therapies in Australia	05-13	MT
Bioxyne to Raise AU$1.45 Million via Share Issuance	04-17	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2023	02-28	CI
Bioxyne Receives License to Manufacture Medical Cannabis, MDMA; Shares Up 50%	02-04	MT
Bioxyne Limited Announces Retirement of N H Chua as Director	11-17	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-31	CI
Bioxyne Unit Joins Forces to Launch B2B Cannabis Trading Platform in Australia; Shares Slump 11%	23-08-15	MT
Bioxyne Limited Extends Amazon Footprint into US and Japan	23-07-16	CI
Australian Shares Track Gains of Wall Street Peers Ahead of Inflation Data, Policy Meetings	23-06-13	MT
Bioxyne Launches Online Healthcare with Technology Partner InstantScripts; Shares Decline 8%	23-06-12	MT
Bioxyne Limited Appoints Jason Hine as Director	23-05-22	CI
Bioxyne Acquires Breathe Life Sciences	23-05-22	MT
Bioxyne Limited acquired Breathe Life Sciences Pty Ltd.	23-05-18	CI
Bioxyne Proceeds With Breathe Life Sciences Acquisition; Shares Fall 4%	23-03-19	MT
Bioxyne Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-23	CI
Bioxyne's Fiscal H1 Revenue Declines	23-01-27	MT
Bioxyne to Acquire Health, Wellness Peer Breathe Life Sciences; Shares Gain 4%	22-12-18	MT
Bioxyne Limited entered into a binding term Sheet to acquire Breathe Life Sciences Pty Ltd for AUD 32 million.	22-12-18	CI
Bioxyne Limited Announces Joining of Mr. Sam Watson the Board as Joint Chief Executive Officer	22-12-18	CI
Bioxyne Sells 49% Stake in Direct Selling Business	22-10-24	MT
Paramount Star Investments Limited reached agreement to acquire 49% of Direct Selling Business of Bioxyne Limited from Bioxyne Limited for $1 million.	22-10-23	CI
Bioxyne Limited Reports Earnings Results for the Full Year Ended June 30, 2022	22-08-29	CI
Bioxyne Limited Announces Board Changes	22-06-07	CI
Bioxyne Posts Higher Sales Revenue in First Nine-Months of FY22	22-04-27	MT

Bioxyne Limited is an Australia-based international consumer health and pharmaceutical company. The Company is focused on health and wellness products, psychotropic and investigational medicines. The Company operates through three segments: Wholesale PCC/USA, Consumer Health Products UK/ EU/JPN, and Pharmaceuticals AUS. Its subsidiary, Breathe Life Sciences (BLS) manufactures, commercializes, and distributes plant-based wellness products and supplements, including cannabidiol (CBD), cannabis extracts, vitamins, manuka honey, skin care products and mushroom complexes. BLS operates in Australia, the United Kingdom, Japan, and Europe with four accredited manufacturing facilities across four countries Japan, Australia, the United Kingdom, and Czechia. The Company direct sales arm and has developed a range of functional food products containing ingredients sourced exclusively from New Zealand and sold in Asia.

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
BIOXYNE LIMITED	-45.45%	8.12M
MODERNA, INC.	+40.80%	53.67B
LONZA GROUP AG	+35.79%	38.86B
IQVIA HOLDINGS INC.	-8.05%	38.76B
CELLTRION, INC.	-8.98%	27.27B
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B
MEDPACE HOLDINGS, INC.	+28.51%	12.18B
BIO-TECHNE CORPORATION	-1.67%	11.96B